Critical Quality Attributes of Lipid Nanoparticles and In Vivo Fate

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Asian Journal of Pharmaceutical Sciences

• Publication date

  2025-09-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.ajps.2025.101092PMCID PMC12686613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.

  2024cited by this paper
• The protein corona from nanomedicine to environmental science

  2023cited by this paper
• Nanoparticle Biodistribution Coefficients: A Quantitative Approach for Understanding the Tissue Distribution of Nanoparticles.

  2023cited by this paper
• Multiphysics-Informed Pharmacokinetic Modeling of Systemic Exposure of Intramuscularly Injected LNPs.

  2023cited by this paper
• Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery

  2023cited by this paper
• Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis.

  2022cited by this paper
• Near‐infrared fluorophores with absolute aggregation‐caused quenching and negligible fluorescence re‐illumination for in vivo bioimaging of nanocarriers

  2022cited by this paper
• Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size

  2022cited by this paper
• The in vivo fate of polymeric micelles.

  2022cited by this paper
• Biological and Intracellular Fates of Drug Nanocrystals through Different Delivery Routes: Recent Development Enabled by Bioimaging and PK Modeling.

  2022cited by this paper
• Unlocking the promise of mRNA therapeutics

  2022cited by this paper
• Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs

  2021cited by this paper
• Lipid Nanoparticles for Drug Delivery

  2021cited by this paper
• Approved and marketed nanoparticles for disease targeting and applications in COVID-19

  2021cited by this paper
• Lipid nanoparticles for mRNA delivery

  2021cited by this paper
• Size-Dependent Absorption through Stratum Corneum by Drug-Loaded Liposomes

  2021cited by this paper
• Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.

  2021cited by this paper
• Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

  2021cited by this paper
• Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.

  2021cited by this paper
• mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

  2021cited by this paper
• Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver

  2021cited by this paper
• Current approaches in lipid-based nanocarriers for oral drug delivery

  2021cited by this paper
• Self-assembled mRNA vaccines

  2021cited by this paper
• Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

  2020cited by this paper
• Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments

  2020cited by this paper
• Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences.

  2020cited by this paper
• When liposomes met antibodies: Drug delivery and beyond.

  2020cited by this paper
• Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection

  2020cited by this paper
• Current status of in vivo bioanalysis of nano drug delivery systems

  2020cited by this paper
• Formulation and Delivery Technologies for mRNA Vaccines.

  2020cited by this paper
• Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery.

  2020cited by this paper
• Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems.

  2019cited by this paper
• Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers.

  2019cited by this paper
• Intrapulmonary Cellular-Level Distribution of Inhaled Nanoparticles with Defined Functional Groups and Its Correlations with Protein Corona and Inflammatory Response.

  2019cited by this paper
• Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.

  2019cited by this paper
• Lipid nanoparticles for delivery of messenger RNA to the back of the eye.

  2019cited by this paper
• Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses

  2019cited by this paper
• Physiologically Based Pharmacokinetic Modeling of Nanoparticles.

  2019cited by this paper
• Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract

  2018cited by this paper
• In vivo fate of lipid-based nanoparticles.

  2017cited by this paper
• Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination.

  2016cited by this paper
• Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery.

  2016cited by this paper
• Analysis of nanoparticle delivery to tumours

  2016cited by this paper
• A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations

  2015cited by this paper
• Principles of nanoparticle design for overcoming biological barriers to drug delivery

  2015cited by this paper
• Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

  2013cited by this paper
• Liposomal drug delivery systems: from concept to clinical applications.

  2013cited by this paper
• Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

  2012cited by this paper
• Nanoparticles as drug delivery systems

  2012cited by this paper
• Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations.

  2012cited by this paper
• Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

  2012cited by this paper
• Nanoparticles for Targeted and Temporally Controlled Drug Delivery

  2012cited by this paper
• The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.

  2011cited by this paper
• Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors.

  2010cited by this paper
• Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles.

  2010cited by this paper
• Physiologically based pharmacokinetic modeling of nanoparticles.

  2010cited by this paper
• Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery

  2010cited by this paper
• Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals

  2010cited by this paper
• Subcellular targeting strategies for drug design and delivery

  2010cited by this paper
• Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.

  2009cited by this paper
• Applications of nanoparticles in topical drug delivery and in cosmetics

  2009cited by this paper
• Pharmacokinetics and biodistribution of nanoparticles.

  2008cited by this paper
• Inhaled nanoparticles--a current review.

  2008cited by this paper
• Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

  2008cited by this paper
• Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles

  2008cited by this paper
• Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

  2007cited by this paper
• Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.

  2007cited by this paper
• Shape effects of filaments versus spherical particles in flow and drug delivery.

  2007cited by this paper
• Detailed identification of plasma proteins adsorbed on copolymer nanoparticles.

  2007cited by this paper
• Inhalation therapy: an historical review.

  2007cited by this paper
• Renal clearance of quantum dots

  2007cited by this paper
• Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.

  2006cited by this paper
• Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.

  2006cited by this paper
• Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

  2006cited by this paper
• Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.

  2006cited by this paper
• Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

  2006cited by this paper
• Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

  2006cited by this paper
• Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush.

  2005cited by this paper
• Hydrolytic degradation of poly(ethylene oxide)-block-polycaprolactone worm micelles.

  2005cited by this paper
• Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.

  2005cited by this paper
• Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity.

  2005cited by this paper
• Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles

  2005cited by this paper
• Skin penetration and distribution of polymeric nanoparticles.

  2004cited by this paper
• A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.

  2004cited by this paper
• Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge.

  2004cited by this paper
• Cosmetic applications for solid lipid nanoparticles (SLN).

  2003cited by this paper
• Functional groups on polystyrene model nanoparticles: influence on protein adsorption.

  2003cited by this paper
• Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles.

  2003cited by this paper
• Biodistribution of meta-tetra(hydroxyphenyl)chlorin incorporated into surface-modified nanocapsules in tumor-bearing mice

  2002cited by this paper
• Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating.

  2002cited by this paper
• INTERFERENCE OF MACROPHAGES WITH IMMUNOTARGETING OF LIPOSOMES

  2002cited by this paper
• Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

  2002cited by this paper
• Experimental and calculated parameters on particle phagocytosis by alveolar macrophages.

  2002cited by this paper
• On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids

  2001cited by this paper
• Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.

  2000cited by this paper
• Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.

  2000cited by this paper
• Electron microscopic demonstration of the penetration of liposomes through skin.

  1997cited by this paper
• Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.

  1997cited by this paper
• Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose.

  1997cited by this paper
• Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.

  1996cited by this paper

• Lipid-Based Colloidal Nanocarriers for Site-Specific Drug Delivery

  2026cites this paper
• Liposomal Nanocarriers in Precision Oncology: Advances and Prospects.

  2026cites this paper